---
id: 250
title: Mycobacterium tuberculosis
category: organisms
subcategory: mycobacteria
tags: [tuberculosis, TB, RIPE, MDR-TB, LTBI, AFB, QuantiFERON]
difficulty: high
---

## Question

What are key considerations for *M. tuberculosis*? Use **"Active TB: RIPE × 2mo → RI × 4mo, LTBI: Rifampin × 4mo or INH × 9mo, Airborne Isolation"** framework.

## Answer

### **Transmission:**

- **Airborne** (droplet nuclei, <5 μm)
- **Close contact** with active pulmonary/laryngeal TB
- **NOT transmitted by:** Fomites, food, casual contact

### **Pathogenesis:**

**Primary TB:**
- **Initial infection** → Ghon complex (parenchymal focus + lymph node)
- **90-95%** develop **latent TB infection (LTBI)** (contained, not infectious)
- **5-10%** progress to **active TB** (primary progressive)

**Latent TB Infection (LTBI):**
- **Asymptomatic, non-infectious**
- **Positive TST/IGRA**, negative cultures, normal CXR
- **5-10% lifetime risk** of reactivation (highest in first 2 years)

**Reactivation TB:**
- **LTBI → active disease** (immunosuppression, age, comorbidities)
- **Apical/posterior upper lobes** (high O₂ favors *M. tb*)

### **Risk Factors for Progression to Active TB:**

**Highest Risk (1-10%/year):**
- **Recent infection** (<2 years)
- **HIV** (CD4 <200: 5-10%/year)
- **TNF-α inhibitors** (infliximab, adalimumab)
- **Immunosuppression** (transplant, chemotherapy, steroids)

**Moderate Risk:**
- **Diabetes, renal failure, malnutrition, smoking**
- **Silicosis, gastrectomy**

### **Diagnosis:**

**Active TB:**

**See Pulmonary TB card for full details:**
- **3 sputum AFB smears + cultures** (acid-fast bacilli)
- **Xpert MTB/RIF** (PCR, detects TB + rifampin resistance in 2h)
- **Chest X-ray:** Upper lobe infiltrates/cavitation
- **Culture** (gold standard, 2-6 weeks for growth)

**Latent TB Infection (LTBI):**

**TST (Tuberculin Skin Test, PPD):**
- **Positive if:**
  - ≥5 mm: HIV, close TB contact, immunosuppressed, CXR consistent with old TB
  - ≥10 mm: High-risk (immigrants, IVDU, healthcare workers, homeless, prisoners)
  - ≥15 mm: Low-risk individuals
- **False positive:** BCG vaccine, non-tuberculous mycobacteria
- **False negative:** Anergy (HIV, severe illness)

**IGRA (Interferon-Gamma Release Assay):**
- **QuantiFERON-TB Gold, T-SPOT.TB**
- **More specific** than TST (NOT affected by BCG)
- **Preferred if:** BCG vaccinated, unlikely to return for TST reading

**Indications for LTBI Testing:**
- **High-risk individuals only** (HIV, close contact, immunosuppressed, immigrants from high-prevalence areas)
- **Do NOT test** if no risk factors (no plan to treat if positive)

### **Treatment:**

**Active Pulmonary TB (Drug-Susceptible):**
- **See Pulmonary TB card (232)**
- **RIPE × 2 months → RI × 4 months** (total 6 months)
- **DOT preferred**

**Latent TB Infection (LTBI):**

**Preferred (Short-Course):**
- **Rifampin 600mg PO daily × 4 months** (high completion rate, well-tolerated)
- **Isoniazid + rifapentine (3HP):** 900mg INH + 900mg rifapentine PO weekly × 12 weeks (DOT)

**Alternative:**
- **Isoniazid 300mg PO daily + pyridoxine 25-50mg daily × 9 months** (historically standard, but lower completion)
- **Rifampin 600mg daily × 3 months** (if cannot do 4 months)

**Contraindications to LTBI Treatment:**
- **Active TB** (must rule out first)
- **Prior adequate TB treatment**
- **Adverse reaction to medications**

**Monitor:**
- **Baseline LFTs** (if risk factors for hepatotoxicity)
- **Monthly symptom check** (jaundice, nausea, abdominal pain)

### **Drug-Resistant TB:**

**MDR-TB (Multidrug-Resistant):**
- **Resistant to rifampin + isoniazid**
- **Treatment:** Fluoroquinolone + bedaquiline + linezolid + others × 18-20 months
- **Consult TB expert**

**XDR-TB (Extensively Drug-Resistant):**
- **MDR-TB + resistance to fluoroquinolone + ≥1 second-line injectable**
- **Very difficult to treat** (high mortality, 40-60%)

### **Infection Control:**

**Airborne Isolation:**
- **Negative pressure room**
- **N95 respirator** (healthcare workers)
- **Continue until:** 3 consecutive negative AFB smears on separate days (usually 2-4 weeks of treatment)

**Discharge Criteria:**
- **Clinical improvement**
- **3 consecutive negative AFB smears**
- **DOT arranged**

### **Contact Investigation:**

**All Close Contacts:**
- **TST/IGRA, CXR**
- **Treat LTBI** if positive (or empiric if high-risk, even if negative initially)
- **Repeat testing at 8-12 weeks** (if initially negative, window period)

### **Special Populations:**

**HIV:**
- **Test all HIV patients for LTBI**
- **Higher risk** of reactivation (5-10%/year if untreated)
- **Start ART within 2-8 weeks** of TB treatment (except TB meningitis, delay 8 weeks to reduce IRIS)

**Pregnancy:**
- **Active TB:** Treat with RIPE (avoid streptomycin)
- **LTBI:** Can defer treatment until postpartum (unless high-risk for progression)

**Children:**
- **Higher risk** of disseminated/miliary TB, TB meningitis
- **Test contacts <5 years** (even if initial tests negative, may need empiric LTBI treatment)

### **Extrapulmonary TB:**

**Common Sites:**
- **Lymph nodes** (cervical, scrofula)
- **Pleural** (exudative effusion, high adenosine deaminase)
- **CNS** (meningitis, tuberculoma)
- **Genitourinary** (sterile pyuria)
- **Bone/spine** (Pott disease)
- **Miliary** (disseminated, hematogenous)

**Duration:** Often **longer** than pulmonary (9-12 months for CNS, bone)

## Key Points

### **Active TB: RIPE × 2mo → RI × 4mo:**
- **6 months total** (drug-susceptible)
- **DOT preferred**

### **LTBI: Rifampin × 4mo (Preferred):**
- **Or INH × 9mo** (lower completion)
- **Or 3HP** (INH + rifapentine weekly × 12 weeks)

### **Airborne Isolation Until 3 Negative Smears:**
- **N95 respirator, negative pressure room**

### **Test LTBI Only if Plan to Treat:**
- **High-risk:** HIV, close contact, immunosuppressed, immigrants

### **HIV: High Risk of Reactivation:**
- **5-10%/year** if untreated LTBI

### **Clinical Pearls:**
- **Active TB:** RIPE × 2mo → RI × 4mo (DOT preferred)
- **LTBI:** Rifampin 600mg daily × 4 months (preferred short-course)
- **Airborne isolation** until 3 consecutive negative AFB smears
- **Test LTBI** only if high-risk + plan to treat
- **HIV:** Screen all for LTBI, start ART within 2-8 weeks of TB treatment
- **Contact investigation:** All close contacts (test + treat LTBI)

## Sources

- [CDC: Tuberculosis Guidelines 2024]
- [ATS/CDC/IDSA: LTBI Treatment 2024]

## Media

N/A
